Treatment for Ventricular Tachycardia Storm

Initial Assessment and Management

• The European Society of Cardiology recommends immediate treatment with intravenous amiodarone combined with beta-blockers for patients experiencing ventricular tachycardia storm, with a dosing regimen of 150 mg over 10 minutes followed by infusion of 1.0 mg/min for 6 hours, then maintenance at 0.5 mg/min, for hemodynamically stable patients 1, 2
• For unstable VT with pulse, the American Heart Association recommends performing immediate synchronized DC cardioversion (100J, 200J, 360J) with sedation if the patient is conscious 3
• The American College of Cardiology recommends pharmacological management for hemodynamically stable VT, with intravenous beta-blockers and amiodarone as first-line therapies 4, 1

Pharmacological Management for VT Storm

First-Line Therapy

• The European Heart Journal recommends intravenous beta-blockers as the single most effective therapy for polymorphic VT storm 1
• The American College of Cardiology recommends intravenous amiodarone at 150 mg infused over 10 minutes, followed by a constant infusion of 1.0 mg/min for 6 hours and then maintenance at 0.5 mg/min, for the treatment of VT storm 4, 2

Alternative Agents

• The American College of Cardiology recommends lidocaine as an alternative agent, with a dosing regimen of 1.0-1.5 mg/kg bolus, and supplemental boluses of 0.5-0.75 mg/kg every 5-10 minutes to a maximum of 3 mg/kg total loading dose, followed by infusion of 2-4 mg/min 4
• The American College of Cardiology recommends procainamide as another alternative agent, with a loading infusion of 20-30 mg/min up to 12-17 mg/kg, followed by infusion of 1-4 mg/min 4

Special Considerations

• The European Heart Journal recommends magnesium (8 mmol) for torsades de pointes if hypomagnesemia is suspected, with a strength of evidence level of IIa 5, 3
• The American College of Cardiology recommends reducing infusion rates of lidocaine in older patients and those with heart failure or hepatic dysfunction to avoid toxicity, with a strength of evidence level of IIb 4
• The American College of Cardiology recommends reducing procainamide infusion rates in patients with renal dysfunction, with a strength of evidence level of IIb 4

Advanced Management Strategies for Refractory VT Storm

• The European Heart Journal recommends overdrive pacing for patients with frequently recurring or incessant VT, with a strength of evidence level of IIb 1
• The European Heart Journal recommends general anesthesia for patients with frequently recurring or incessant VT, with a strength of evidence level of IIb 1
• The European Heart Journal recommends spinal cord modulation for some patients with frequently recurring or incessant VT, with a strength of evidence level of IIb 1

Addressing Underlying Causes

• The European Heart Journal recommends aggressive treatment of heart failure in patients with left ventricular dysfunction due to prior myocardial infarction and ventricular tachyarrhythmias, with a strength of evidence level of I 1
• The European Heart Journal recommends aggressive treatment of myocardial ischemia in patients with ventricular tachyarrhythmias, with a strength of evidence level of I 1
• The European Heart Journal recommends coronary revascularization when there is clear evidence of acute myocardial ischemia preceding ventricular fibrillation, with a strength of evidence level of I 1

Treatment for Ventricular Tachycardia Storm

Pharmacological Management

• The American College of Cardiology recommends lidocaine as an alternative or in addition to amiodarone, particularly when VT is thought to be related to myocardial ischemia, with a dosing regimen of 1.0-1.5 mg/kg bolus, and supplemental boluses of 0.5-0.75 mg/kg every 5-10 minutes to a maximum of 3 mg/kg total loading dose, followed by infusion of 2-4 mg/min 6
• For drug-refractory polymorphic VT, the American College of Cardiology suggests implementing aggressive measures to reduce myocardial ischemia, including beta-blockade, intra-aortic balloon pumping, and emergency PTCA/CABG surgery 6

Management of Ventricular Tachycardia Storm

Indications for Isoproterenol

• The European Society of Cardiology recommends isoproterenol as a temporary treatment for recurrent pause-dependent torsades de pointes in patients without congenital long QT syndrome, with a Class IIa recommendation and Level B evidence 7, 8
• Isoproterenol infusion can be effective for VT/VF storm specifically in short QT syndrome, with a Class IIa recommendation and Level C-LD evidence, according to the American College of Cardiology 9
• The mechanism of isoproterenol in acquired long QT settings is to increase heart rate, eliminating the pauses that trigger torsades, as stated by the European Heart Society 7, 8

Standard VT Storm Management

• Intravenous beta-blockers are the single most effective therapy for polymorphic VT storm, as recommended by the European Heart Society 7, 8
• Overdrive pacing may be considered for frequently recurring or incessant VT, with a Class IIb recommendation, according to the European Heart Society 7, 8
• VT ablation should be pursued after initial stabilization with amiodarone or procainamide, with a Class IIa recommendation, as stated by the European Heart Society 7, 8

Critical Pitfalls to Avoid

• The European Heart Society warns that isoproterenol increases myocardial oxygen demand and can worsen ischemia-driven VT, and is contraindicated in hypotensive states 7, 8
• The American Heart Association emphasizes the importance of identifying the underlying mechanism before considering isoproterenol, as it is only appropriate for pause-dependent torsades, short QT syndrome, or Brugada syndrome 7, 9, 8
• The American College of Cardiology recommends aggressively treating heart failure and myocardial ischemia in all VT storm patients, with a Class I recommendation 7, 8

Management of Ventricular Storm

Diagnosis and Treatment

• The European Society of Cardiology recommends immediate coronary angiography for recurrent polymorphic VT/VF, as it may indicate incomplete reperfusion or recurrent ischemia 10, 11
• The European Society of Cardiology suggests that complete and rapid revascularization is recommended for myocardial ischemia in recurrent VT/VF, although the specific citation for this is not provided, a related recommendation is that prompt coronary revascularization is recommended when clear evidence of acute ischemia precedes VF 10, 11

Alternative Antiarrhythmic Agents

• The European Heart Journal guidelines suggest that lidocaine may be considered for recurrent VT/VF not responding to beta-blockers or amiodarone, with a loading dose of 1.0-1.5 mg/kg IV bolus, although the specific citation for the dose is not provided, the use of lidocaine is mentioned 10, 11
• The European Heart Journal guidelines recommend that procainamide is useful in patients without severe heart failure or acute infarction, with a loading dose of 20-30 mg/min up to 10-12 mg/kg, although the specific citation for the dose is not provided, the use of procainamide is mentioned 10, 11

Advanced Rescue Therapies for Refractory Cases

• The European Society of Cardiology recommends catheter ablation for patients with recurrent VT/VF despite optimal medical treatment, with urgent ablation able to acutely terminate electrical storm 10, 11, 12
• The European Society of Cardiology suggests that mechanical circulatory support, such as an LV assist device or extracorporeal life support, should be considered in hemodynamically unstable patients with recurrent VT/VF despite optimal therapy 12

Critical Pitfalls to Avoid

• The European Heart Journal guidelines recommend avoiding Class IC antiarrhythmics, such as flecainide and propafenone, in patients with prior MI or ACS 10, 11
• The European Heart Journal guidelines recommend that prophylactic antiarrhythmic drugs, other than beta-blockers, are not recommended and may be harmful (Class III) 11, 12